Genome/Transcriptome Sequencing Project Promises PGx Strategy for Rare Cancers

A recent study combined analysis of a patient's tumor genome and transcriptome sequences to guide treatment of tongue adenocarcinoma with Pfizer's Sutent (sunitinib) and Bayer's Nexavar (sorafenib).

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories